Impact of HIV-1 and Aging on Mucosal Vaccine Responses

Running, not enrolling · Early Phase 1

Conditions studied: HIV-1-infection, Human Immunodeficiency Virus, HIV/AIDS, HIV Infections

In brief

The purpose of this study is to learn more about both HIV-1 infection and advancing age, and their association with increased risk of serious infection and impaired response to the Prevnar 13 vaccine.

Key facts

Study ID

NCT03729778

Run by

VA Eastern Colorado Health Care System

People needed

100

Starts

2017-01-18

Expected to finish

2028-01-01

Last updated by the study team

2026-07-29

Who can join

Age: 21 and older, up to 75. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Veterans only (accessibility to non-veterans pending)
• Age 21-45 or 55-75 Years Old
• Have not received pneumococcal vaccine Prevnar PCV-13
• Able to attend 2-3 study visits over 1 month
• HIV+:
• Undetectable Viral load
• HIV negative controls:
• no history or risks for HIV infection

You may not qualify if…

• Spleen removed
• Chronic Kidney disease (creatinine ≥ 2.0 mg/dL)
• Active liver disease
• Currently taking: Corticosteroids (prednisone, medrol, etc), Chemotherapy, Immunosuppressive medication (cyclosporine, methotrexate, azathioprine, infliximab, adalimumab, rituximab, etanercept, etc), or illicit drugs (methamphetamine, cocaine, crack, or heroin)

Where it is running

• Rocky Mountain Regional VA Medical Center — Aurora, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.